Xenetic Biosciences, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 21, 2024. This is an annual report, not a standalone fourth-quarter report. The filing text does not provide a clear standalone Q4 financial result.
Business context
Xenetic is a clinical-stage biopharmaceutical company focused on immune-oncology. Its primary development priority is a systemic DNase platform intended to target neutrophil extracellular traps (NETs) and potentially improve existing cancer treatments. Initial targets include pancreatic cancer and other locally advanced or metastatic solid tumors. The program remained preclinical; the company was working toward a first-in-human study. Xenetic also receives PolyXen royalty revenue, primarily from a Takeda sublicense. No drug candidate had received marketing approval.
Financial performance and liquidity
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Revenue, all royalty revenue | $2.54 million | $1.71 million |
| Research and development expense | $3.49 million | $4.77 million |
| General and administrative expense | $3.56 million | $3.65 million |
| Operating loss | $4.52 million | $6.72 million |
| Net loss | $4.13 million | $6.55 million |
| Basic and diluted loss per share | $2.71 | $4.61 |
| Net cash used in operating activities | $4.11 million | $4.65 million |
| Cash at year-end | $8.98 million | $13.10 million |
| Working capital at year-end | $8.8 million | $12.6 million |
Takeda sublicense royalties accounted for all reported revenue: approximately $2.54 million in 2023, based on single-digit royalties on covered product sales. The company reported no product sales. Operating costs exceeded revenue, so the company remained loss-making; a conventional operating margin is not meaningful in this context.
Reported R&D expense fell 26.7%, primarily because 2022 included $1.79 million of acquired in-process R&D expense associated with licensing the DNase platform, with no comparable charge in 2023. Excluding that 2022 item, 2023 R&D expense increased approximately 17.4%, reflecting greater preclinical DNase spending. Revenue increased 48.8%; net loss narrowed 36.9%.
At December 31, 2023, total assets were $10.61 million, total liabilities were $0.81 million, and stockholders’ equity was $9.80 million. The balance sheet reports no outstanding debt. The Pharmsynthez loan was repaid in May 2023; no amount remained outstanding at year-end. Investing cash flow was zero in 2023, and there were no financing cash flows in either 2023 or 2022. Lease obligations disclosed at year-end totaled approximately $30,000.
Management stated that substantial doubt exists about the company’s ability to continue as a going concern, given its accumulated losses and expected future operating losses. Management nevertheless believed existing resources would fund operations for at least 12 months from issuance of the financial statements, while noting that additional capital may be needed longer term. The independent auditor issued an unqualified opinion and identified the going-concern assessment and royalty revenue recognition as critical audit matters.
Developments, outlook, and key risks
- Development and collaborations: In 2023, Xenetic continued preclinical DNase work, including research arrangements with Scripps Research (funding of up to $938,000) and the University of Virginia (including an option to license resulting intellectual property). Volition funded an exploratory DNase-armored CAR T research program; approximately $0.1 million had been funded through year-end.
- Manufacturing commitment: The Catalent project for cGMP manufacture of human DNase I was estimated to cost up to approximately $5 million, excluding certain fees and alternatives. Xenetic had paid approximately $2.5 million through year-end; amounts and timing may vary.
- Other programs: XCART development was suspended as resources shifted to DNase. ErepoXen development is not being pursued by Xenetic; its partner reported deficiencies in the Russian registration dossier and was working on a mitigation strategy.
- Outlook: The filing describes the objective of advancing systemic DNase toward a first-in-human study and refers to multiple potential milestones over the next 12–24 months, but gives no specific financial guidance or assured trial-start date. Management expects continued R&D spending and may need further financing.
- Funding and dilution: Xenetic has no committed external funding source. Future equity or debt financing, collaborations, or licensing may be unavailable or on unfavorable terms, and could dilute shareholders, restrict operations, or require surrendering technology rights. An ATM facility was available, but no shares were sold under it in 2023.
- Execution risks: DNase is early-stage and the business is substantially dependent on its success. Clinical, regulatory, safety, patient-enrollment, manufacturing, collaboration, intellectual-property, market-acceptance, and reimbursement risks could delay or prevent development or commercialization.
- Listing and ownership: Xenetic regained Nasdaq minimum-bid-price compliance in May 2023 after a 1-for-10 reverse stock split, but continued compliance is not assured. Series B preferred stock has senior liquidation rights and potential conversion dilution; common shares and other securities may also be dilutive.
- Concentration and unusual items: Revenue depended on a single royalty source. The 2023 improvement in reported R&D expense reflects the absence of the 2022 DNase licensing-related IPR&D charge. A $0.4 million increase in net interest income reflected higher rates and interest on the repaid Pharmsynthez loan.
Important facts for investors to verify
- Cash runway assumptions and the timing, amount, and terms of any additional financing, given the going-concern disclosure.
- DNase preclinical progress, regulatory preparation, manufacturing readiness, and whether a first-in-human study and stated development milestones remain on schedule.
- Takeda royalty reports, covered-product sales trends, and the risk of reliance on this single revenue source.
- Actual costs and payment timing for Catalent and research collaborations, including any changes to the estimated manufacturing budget.
- Nasdaq listing compliance, share-count changes, and potential dilution from preferred stock, warrants, options, or future offerings.
- Progress by Pharmsynthez on correcting the ErepoXen registration dossier and any resulting potential royalties.